RepliCel Life Sciences (TSXV: RP) CEO: We’re Excited About This Year’s Developments

Share on Linkedin

RepliCel Life Sciences is a regenerative medicine company focused on developing cell therapies for the treatment of sun-damaged skin, pattern baldness, and chronic tendon degeneration


RepliCel Life Sciences Inc. (TSXV: RP) President and CEO Lee Buckler talks with SmallCapPower at the Bloom Burton Healthcare Investor Conference in Toronto about this regenerative medicine company that is focused on developing cell therapies for the treatment of aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. Find out what new developments RepliCel Life Sciences has planned for 2017 by watching our short video interview.

For more video coverage from the Bloom Burton Healthcare Investor Conference please click here

Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: